Figure S1 from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer

Figure S1 from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer

<p>Recurrence per PDL1 and MPR</p>

Gorde:
Xehetasun bibliografikoak
Egile nagusia: Samuel Rosner (15054884) (author)
Beste egile batzuk: Joshua E. Reuss (15054887) (author), Marianna Zahurak (15054890) (author), Jiajia Zhang (15054893) (author), Zhen Zeng (15054896) (author), Janis Taube (15054899) (author), Valsamo Anagnostou (14961731) (author), Kellie N. Smith (15054902) (author), Joanne Riemer (15054905) (author), Peter B. Illei (15054908) (author), Stephen R. Broderick (15054911) (author), David R. Jones (15044613) (author), Suzanne L. Topalian (15031475) (author), Drew M. Pardoll (14953549) (author), Julie R. Brahmer (15054914) (author), Jamie E. Chaft (14937195) (author), Patrick M. Forde (15054917) (author)
Argitaratua: 2025
Gaiak:
Cancer
Immuno-oncology
Clinical Research and Trials
Clinical Trial Results
Immunotherapy
Checkpoint blockade
Lung Cancer
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
Deskribapena
Gaia:<p>Recurrence per PDL1 and MPR</p>

Antzeko izenburuak